Markets:

Overview

News

Currencies

International

Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

23.66 -0.19 (-0.80%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 Next >

Innoviva Inc (NASDAQ:INVA) Presents a Compelling Value Investment Case ↗

February 10, 2026

Via Chartmill

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗

January 08, 2026

Via MarketBeat

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

December 16, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

November 13, 2025

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Beyond The Numbers: 5 Analysts Discuss Innoviva Stock ↗

September 30, 2025

Via Benzinga

A Look Into Healthcare Sector Value Stocks ↗

May 15, 2023

Via Benzinga

Value Investing Case Study: INNOVIVA INC (NASDAQ:INVA) ↗

November 11, 2025

Discover Innoviva (INVA), a potential value stock with strong fundamentals. Its attractive valuation, healthy balance sheet, and solid profitability suggest it trades below intrinsic worth.

Via Chartmill

Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks ↗

September 08, 2025

Discover Innoviva (INVA), a value stock with strong fundamentals. It trades below intrinsic value, boasts a healthy balance sheet, and has promising growth prospects in biopharma.

Via Chartmill

Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential ↗

August 18, 2025

Innoviva (INVA) is a value stock with strong valuation metrics, solid financial health, and growth potential, making it an attractive pick for value investors.

Via Chartmill

Expert Outlook: Innoviva Through The Eyes Of 4 Analysts ↗

August 11, 2025

Via Benzinga

This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday ↗

August 11, 2025

Via Benzinga

Innoviva (INVA) Q2 Sales Jump 64% ↗

August 06, 2025

Via The Motley Fool

This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

July 14, 2025

Via Benzinga

Rep. George Whitesides Has Sold Up to $5.18M Worth Of Innoviva Stock: Here's What You Should Know ↗

April 24, 2025

Via Benzinga

Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 01, 2025

Via Benzinga

US Stock: Innoviva ↗

November 27, 2024

Innoviva Incorporated is a healthcare focused asset management company. The Company intends to participate in the development, commercialization, and financial management of bio-pharmaceuticals.

Via Talk Markets

Topics Stocks / Equities

INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024 ↗

July 31, 2024

INVA stock results show that Innoviva missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 ↗

July 09, 2024

A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher.

Via InvestorPlace

3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge ↗

June 27, 2024

Discover three high-growth stock picks set for unprecedented surges in the metals, marine transportation, and pharmaceutical industries.

Via InvestorPlace

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs ↗

June 18, 2024

Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products.

Via Benzinga

3 Under-$20 Stocks That Could Make You a Fortune ↗

May 31, 2024

Discover three under-$20 stocks that could make a fortune in the pharmaceuticals, entertainment, and application software industries.

Via InvestorPlace

INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

INVA stock results show that Innoviva beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

5 Value Stocks In The Healthcare Sector ↗

March 04, 2024

Via Benzinga

If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names ↗

January 10, 2024

Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.

Via InvestorPlace

Chart Of The Day: Innoviva - Individual Investor Favorite ↗

January 08, 2024

100% technical buy signals 14 new highs and up 12.87% in the last month 36.40+ Weighted Alpha

Via Talk Markets

A Look Into Healthcare Sector Value Stocks ↗

October 02, 2023

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

July 31, 2023

Via Benzinga

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now ↗

July 11, 2023

With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look.

Via InvestorPlace

AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter ↗

May 24, 2023

Via Benzinga

Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying ↗

May 16, 2023

Although US stocks closed higher on Monday, there were a few notable insider trades.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.